<DOC>
	<DOCNO>NCT02499263</DOCNO>
	<brief_summary>This prospective , single country , multi-center study Ulcerative Colitis ( UC ) patient treat adalimumab . 200 subject enrol approximately 20 site . The baseline assessment perform prior first dose adalimumab ( Visit1 ) . Study visit conduct week 8 , 16 , 24 , 32 , 40 , 48 56 accordance clinical practice . All subject one Follow-up safety approximately 70 day last dose adalimumab</brief_summary>
	<brief_title>A Prospective Non-interventional Multicentre Study Evaluate Effectiveness Adalimumab Korean Patients With Ulcerative Colitis ( UC ) Identify Potential Predictors Clinical Response Routine Clinical Practice</brief_title>
	<detailed_description>This Observation study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject must adult &gt; = 19 year Subject active moderatetosevere ulcerative colitis patient Mayo score â‰¥ 6 point endoscopic subscore &gt; = 2 point despite treatment corticosteroid and/or immunosuppressant Subjects must tuberculosis ( TB ) Screening Assessment accordance Korean reimbursement guideline Subjects start adalimumab treatment normal clinical practice set Subject must provide write authorization form use personal and/or health data prior entry study Female subject pregnant breast feeding Subject applies contraindication adalimumab Subject participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adalimumab trough level</keyword>
	<keyword>Fecal Calprotectin</keyword>
	<keyword>Fecal microbiota</keyword>
</DOC>